IL159759A0 - Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression - Google Patents

Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression

Info

Publication number
IL159759A0
IL159759A0 IL15975902A IL15975902A IL159759A0 IL 159759 A0 IL159759 A0 IL 159759A0 IL 15975902 A IL15975902 A IL 15975902A IL 15975902 A IL15975902 A IL 15975902A IL 159759 A0 IL159759 A0 IL 159759A0
Authority
IL
Israel
Prior art keywords
gene expression
targeted inhibition
derivatives
novel
oligoribonucleotide derivatives
Prior art date
Application number
IL15975902A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL159759A0 publication Critical patent/IL159759A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IL15975902A 2001-07-12 2002-07-05 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression IL159759A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133915A DE10133915A1 (de) 2001-07-12 2001-07-12 Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
PCT/EP2002/007483 WO2003008595A2 (de) 2001-07-12 2002-07-05 Neue oligoribonucleotid-derivate zur gezielten hemmung der genexpression

Publications (1)

Publication Number Publication Date
IL159759A0 true IL159759A0 (en) 2004-06-20

Family

ID=7691545

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15975902A IL159759A0 (en) 2001-07-12 2002-07-05 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
IL159759A IL159759A (en) 2001-07-12 2004-01-07 History of oligoribonucleotide for deliberate inhibition of gene expression, medicinal preparations containing them, methods for their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159759A IL159759A (en) 2001-07-12 2004-01-07 History of oligoribonucleotide for deliberate inhibition of gene expression, medicinal preparations containing them, methods for their preparation and use

Country Status (14)

Country Link
US (2) US20030105052A1 (ja)
EP (1) EP1414961B1 (ja)
JP (1) JP4690649B2 (ja)
AT (1) ATE371734T1 (ja)
AU (1) AU2002325305B2 (ja)
CA (1) CA2453295C (ja)
CY (1) CY1107776T1 (ja)
DE (2) DE10133915A1 (ja)
DK (1) DK1414961T3 (ja)
ES (1) ES2289131T3 (ja)
IL (2) IL159759A0 (ja)
MX (1) MXPA04000178A (ja)
PT (1) PT1414961E (ja)
WO (1) WO2003008595A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
DE10350256A1 (de) * 2003-10-01 2005-06-02 Grünenthal GmbH PIM-1-spezifische siRNA-Verbindungen
DE102004011687A1 (de) * 2004-03-10 2005-10-13 Grünenthal GmbH VGLUT-spezifische dsRNA-Verbindungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3717436A1 (de) * 1987-05-23 1988-12-08 Hoechst Ag Verfahren zur herstellung von doppelstraengiger dna
KR930016437A (ko) 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6010907A (en) * 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) * 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
WO2000004189A1 (en) * 1998-07-14 2000-01-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides

Also Published As

Publication number Publication date
CY1107776T1 (el) 2013-06-19
EP1414961A2 (de) 2004-05-06
DK1414961T3 (da) 2007-11-26
PT1414961E (pt) 2007-09-25
JP4690649B2 (ja) 2011-06-01
US7635769B2 (en) 2009-12-22
US20030105052A1 (en) 2003-06-05
WO2003008595A2 (de) 2003-01-30
ES2289131T3 (es) 2008-02-01
AU2002325305B2 (en) 2007-05-17
EP1414961B1 (de) 2007-08-29
JP2005500050A (ja) 2005-01-06
DE50210819D1 (de) 2007-10-11
WO2003008595A3 (de) 2004-01-22
US20060025374A1 (en) 2006-02-02
ATE371734T1 (de) 2007-09-15
MXPA04000178A (es) 2004-03-18
DE10133915A1 (de) 2003-02-06
CA2453295C (en) 2012-09-25
IL159759A (en) 2012-05-31
CA2453295A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
DK1409670T3 (da) Syntetiske dobbeltstrengede oligonukleorider til målrettet hæmning af genekspressionen
ZA200109995B (en) Nematicidal Trifluorobutenes.
HK1070008A1 (en) Combination of cytochome p 450 dependent protease inhibitors
IL135590A0 (en) A process for the reduction of oxiranyl epothilones to olefinic epothilones
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
AU2003268096A8 (en) Antisense modulation of nav1.3 expression
MX9801190A (es) Inhibidores de prolil endopeptidasa.
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
SI1377574T1 (ja)
AU2487602A (en) Isolated luciferases and the use thereof
AP2000001911A0 (en) Process for the synthesis of hiv protease inhibitors
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
PT1042288E (pt) Inibidores de tripeptidil peptidase
AU2002219992A1 (en) Targeted regulation of gene expression
BR9809439A (pt) Processos para preparação de benzotiofenos
GB0113920D0 (en) Composition
AU6121901A (en) Felbamate derived compounds
RO116896B1 (ro) Derivaţi pseudocarbaciclinici şi procedeu pentru prepararea acestora
BR9803717A (pt) ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase.
HK1039451A1 (en) Use of catechol derivatives as proteinase inhibitors
IT1316990B1 (it) Metodo per aumentare l'espressione genica per geni trasfettati.